Back

Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use

2 September 2019 (09:24 - 09:42)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors: from cells to patients Lipid-Lowering Agents ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Stefan Mulverstedt

Bispebjerg University Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail
State of the Art - PCSK9 in inhibitors therapy in clinical therapy
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)
Abstract
Presentation thumbnail
The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.
Mrs A. Tsouka (Ioannina, GR)
Abstract Slides Video
Presentation thumbnail
Positioning PCSK9 inhibitors therapy in clinical practice.
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors: from cells to patients

The Event

Event poster

ESC Congress 2019

2 September 2019 09:24 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
New trial evidence in the field of lipid management
thumbnail
Congress Presentation
2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias